Pinned Tweet
Extremely happy that our work got accepted in #ATVB! We functionally profiled 400 biobank samples, linking cellular lipid uptake, storage and handling to treatment outcomes of statin therapy and residual cardiovascular risk.
ahajournals.org/doi/10.1161/…
Simon Pfisterer retweeted
Productive days at @American_Heart conference in Chicago! 🫀Key takeaway: we need to better understand local #inflammation and its pathways. This is where #MONCYTEHealth brings value: revealing immune cell activity driving inflammation in vessel walls with a simple blood sample.
Excited to share our latest FH study! We show concordance across functional assays, strengthening variant classification in ClinVar.
@society_eas @majharulmamun @HelsinkiUniMed @helsinkiuni atherosclerosis-journal.com/…
Simon Pfisterer retweeted
Day 2 at ESC @escardio 🫀
Interesting scientific sessions on lipids, inflammation, pharmacotherapy and meetings with amazing collaborators from South Africa to Bosnia 🫶🏻
At MONCYTE Health we are looking for a laboratory technician. Are you ready to join a vibrant and exciting team, pushing boundaries in precision medicine? Please apply!
More information can be found here:
moncytehealth.com/open-posit…
The closing date for applications is: 30.11.2025
Simon Pfisterer retweeted
Honoured to have participated in the inaugural @WHXTech in Dubai. Thank you to the organizers and speakers for a well-curated programme that fostered collaboration and focused discussions at the intersection of health and AI. Meaningful connections and an exceptional city!
Simon Pfisterer retweeted
Wonderful to present our data at @escardio at one of the most important cardiology conferences in Madrid 🇪🇸 — over 33k+ participants from 150 countries! Grateful for our team’s contribution and inspiring connections. @society_eas #MoncyteHealth
It was great to present our latest data at the #ESC Congress in #Madrid and to catch up with colleagues and friends at one of the most important cardiology conferences! Huge event with great science and clinical data + Madrid is nice! @society_eas
Simon Pfisterer retweeted
Join us at @escardio Congress in Madrid on 30 August, 13:15-14:00! Find out how alterations in cellular lipid metabolism link to outcomes of statin treatment & residual #cardiovascular risk - a step toward personalized cardiovascular care.
#ESC2025 #highcholesterol
It was very nice to record this podcast. Talking about our research at @helsinkiuni and forming the spin-out company moncytehealth.com!
@TamaraAlagirova @helsinkiuni
Dr @SimonPfisterer, Group Leader at the University of Helsinki and Chief Scientific Officer of Moncyte Ltd., was our guest in the latest episode of AtheroTalk. His work bridges cutting-edge research and clinical applications in dyslipidaemia and cardiovascular disease. We talk about his academic journey, his move into biotech, and his vision for the future of precision medicine in atherosclerosis.
🎧 Spotify: eas.to/ATHTalkE16S
🎧 Apple Podcasts: eas.to/ATHTalkE16A
🎧 Youtube: eas.to/ATHTalkE16Y @ProfKausikRay @KatiOorni
Simon Pfisterer retweeted
Fun discussion with @ErinMichos @smsaadatagah and Daniel Gaudet on a pragmatic approach to the patient with #chylomicronemia @nationallipid @ASPCardio @BCMHeart @BCMDeptMedicine @BCM_CVRI
New episode of Lipid Insights is live!🎙️
Dive into expert guidance on recognizing & managing persistent chylomicronemia, featuring Drs. Gaudet, Michos, Ballantyne, & Saadatagah. Listen now on your favorite podcast platform, YouTube, or at lipid.org/lipidinsights.
@ASPCardio @CBallantyneMD @ErinMichos @smsaadatagah
#Lipids #SciencePodcast #MedicalPodcast #Podcast #AcutePancreatitis
It was great to record an #AtheroTalk podcast and talk about our research and establishing the startup company moncytehealth.com! A big thank you to the team, especially Sanne M. and @azinkh96 for interviewing me and doing the recording. It has been a very nice experience!
Have you checked out the latest #AtheroTalk episode yet? 🎙️ It’s out now and worth a listen! @society_eas #academic #podcast
🎧 Spotify:
open.spotify.com/episode/5X2…
Thank you @MaxTamlander and @samrip for your help and contributions for the polygenic risk scores
44
This opens up large opportunities for novel precision medicine applications in dyslipidemia and cardiovascular disease.
1
26
The technology will be developed further by moncytehealth.com to bring the first actionable diagnostic solution to dyslipidemia and cardiovascular disease, optimizing treatment selection and residual risk assessment.
@TamaraAlagirova @helsinkiuni
1
33
It has been a great pleasure to write this summary about new developments regarding LDL structure, function and cellular uptake, together with Gilles Lambert!
@CaixaResearch @helsinkiuni
@HiLIFE_helsinki #PerMedFH nature.com/articles/s41569-0…
Simon Pfisterer retweeted
Great start of our Horizon Europe project #FHEARLY with an outstanding group of colleagues @FUlisboa @LaleTokgozoglu @magdadaccord @SimonPfisterer @CROCETERA @MeralKayikcoglu
Simon Pfisterer retweeted
We wrote an editorial discussing the importance of the conformation of apoB. ApoB-100: The guardian of LDL stability - Atherosclerosis atherosclerosis-journal.com/…
This editorial was insipired by an article published earlier in @ATHjournal
atherosclerosis-journal.com/…
Simon Pfisterer retweeted
Exciting news 🚀 MONCYTE Health joins EUR 7 million Horizon Europe funded international consortium for earlier diagnosis and management of Familial Hypercholesterolemia (FH)🔥
Full Press Release here: moncytehealth.com/?p=3908
My followers dropped by 25% during the past 6 weeks. ➕ Content on this platform is getting increasingly difficult to enjoy. Checking out new options: spfisterer.bsky.social
1
45




































